Subject
Radiology, Nuclear Medicine and imaging
Reference5 articles.
1. 1. Satoh TK, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer HD, et al. IL- 36? drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. The Journal of clinical investigation. 2020;130(3):1417-30. https://doi.org/10.1172/JCI128678
2. 2. Chularojanamontri L, Tuchinda P, Likitwattananurak C, Pongparit K, Rujitharanawong C, Ithimakin S, et al. Cutaneous toxicities of epidermal growth factor receptor inhibitors: A prospective study in 60 Asian patients. Asian Pacific journal of allergy and immunology. 2019;37(1):12-8.
3. 3. Gisondi P, Geat D, Mattiucci A, Lombardo F, Santo A, Girolomoni G. Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer. Dermatology (Basel, Switzerland). 2021;237(6):929-33.https://doi.org/10.1159/000513233
4. 4. Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C, et al. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Bioscience trends. 2019;12(6):537-52.https://doi.org/10.5582/bst.2018.01246
5. 5. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012;380(9859):2163-96. https://doi.org/10.1016/S0140-6736(12)61729-2